ABT-122(靶向TNF与IL-17双可变域免疫球蛋白)在类风湿关节炎患者中的安全性、耐受性与药效学研究
两项I期安慰剂对照多剂量递增研究汇总了44例接受稳定剂量甲氨蝶呤的类风湿关节炎患者,评估ABT-122(同时靶向TNF和IL-17A的双可变域免疫球蛋白)的安全性、耐受性及探索性药效学。结果显示ABT-122总体安全性良好,不良事件与感染发生率与安慰剂相似,仅1例严重不良事件,无全身超敏反应或剂量限制性毒性;治疗后CXCL9、CXCL10、CCL23和可溶性E-选择素较安慰剂显著下降。
要点
- ABT-122在主要为非活动性RA患者中安全性和耐受性良好,不良事件与安慰剂相似。
- 仅1例严重不良事件,无全身超敏反应、剂量限制性毒性或严重感染报告。
- ABT-122治疗后CXCL9、CXCL10、CCL23和可溶性E-选择素较安慰剂显著降低。
核心结论
- 两项I期研究提示,ABT-122同时中和TNF和IL-17具有可接受的安全性特征,值得在TNF和IL-17A驱动的免疫介导炎症性疾病中进一步探索治疗潜力。
研究设计与样本
- 汇总分析两项I期、安慰剂对照、多剂量递增研究,纳入44例主要为非活动性RA且接受稳定剂量甲氨蝶呤(2.5-25 mg/周)的患者。
- 患者随机接受皮下安慰剂、ABT-122 1 mg/kg每两周一次(共4剂)或ABT-122 0.5、1.5、3 mg/kg每周一次(共8剂),末次给药后随访至第92天。
主要发现
- ABT-122治疗未观察到临床显著的安全性发现,治疗中出现的不良事件发生率与安慰剂相似。
- ABT-122治疗患者中仅观察1例严重不良事件,无全身超敏反应或剂量限制性毒性。
- ABT-122治疗患者感染发生率与安慰剂相似,未报告严重感染。
- ABT-122治疗后CXCL9、CXCL10、CCL23和可溶性E-选择素水平较安慰剂显著降低。
- 尽管患者RA基本为非活动性,探索性临床参数提示ABT-122治疗可能具有抗炎效应。
临床怎么用
- ABT-122双靶向TNF和IL-17A的安全性特征支持在TNF和IL-17A驱动的免疫介导炎症性疾病中进一步开展治疗潜力探索。
局限性
- 本研究为I期研究,样本量44例,患者主要为非活动性RA,临床疗效结论仅为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tumor necrosis factor (TNF) and interleukin-17 (IL-17) independently contribute to the pathophysiology of rheumatoid arthritis (RA). ABT-122 is a novel dual variable domain immunoglobulin that selectively and simultaneously targets human TNF and IL-17A. The aim of treatment with ABT-122 is to evoke a greater clinical response than that achieved by targeting either cytokine alone. This study was undertaken to present the pooled safety, tolerability, and exploratory pharmacodynamics of ABT-122 based on 2 phase I, placebo-controlled, multiple ascending-dose studies in patients with primarily inactive RA. METHODS: Patients (n = 44) receiving stable dosages of methotrexate (2.5-25 mg/week) were randomized to receive subcutaneous placebo, ABT-122 1 mg/kg every other week (4 doses), or ABT-122 0.5, 1.5, or 3 mg/kg weekly (8 doses) and were evaluated through 45 days after the last dose (day 92). Serum samples for the assessment of inflammation markers and chemokines were collected at baseline and on postdose days 3, 5, 8, 15, 29, 57, 64, 78, and 92. RESULTS: No clinically significant findings regarding the safety of ABT-122 were observed. The rates of treatment-emergent adverse events (AEs) were similar in patients receiving ABT-122 and those receiving placebo. Only 1 serious AE (and no systemic hypersensitivity reactions or dose-limiting toxicities) was observed in patients treated with ABT-122. The incidence of infections was similar between patients treated with ABT-122 and those receiving placebo, with no serious infection reported. The levels of CXCL9, CXCL10, CCL23, and soluble E-selectin were significantly decreased following ABT-122 treatment relative to placebo treatment. Although patients had essentially inactive RA, exploratory clinical parameters suggested potential antiinflammatory effects following treatment with ABT-122. CONCLUSION: The results of these phase I studies suggest that dual neutralization of TNF and IL-17 with ABT-122 has characteristics acceptable for further exploration of therapeutic potential in TNF- and IL-17A-driven immune-mediated inflammatory diseases.
引用
- Fleischmann RM, Wagner F, Kivitz AJ, et al. Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2017. PMID: 28941216. doi:10.1002/art.40319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。